| Identification | Back Directory | [Name]
Keliximab | [CAS]
174722-30-6 | [Synonyms]
Keliximab
Idec ce91
Keliximab [inn]
Immunoglobulin G 1 (human-macaca monoclonal ce91 gamma1-chain anti-human antigen cd 4), disulfide with human-macaca monoclonal ce91 lambda-chain, dimer
Immunoglobulin G1, anti-(human cd4 (antigen)) (human-macaca monoclonal ce91 gamma1-chain), disulfide with human-macaca monoclonal ce91 lambda-chain, dimer |
| Hazard Information | Back Directory | [Uses]
Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research[1][2]. | [in vivo]
Keliximab (5-125 mg/kg; i.v., once) decreases CD4+ T cells[1]. | Animal Model: | Transgenic mice bearing human CD4 molecules on their T cells[1] | | Dosage: | 5-125 mg/kg | | Administration: | Intravenous injection, 5-125 mg/kg, once | | Result: | Dose-dependently down-modulated CD4 and rapidly declined the number of circulating CD4+ T cells compared with clenoliximab.
|
| [References]
[1] Sharma A, et al. Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4. J Pharmacol Exp Ther. 2000 Apr;293(1):33-41. PMID:10734150
[2] Anderson D, et al. A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4. Clin Immunol Immunopathol. 1997 Jul;84(1):73-84. DOI:10.1006/clin.1997.4363 |
|
| Company Name: |
Biolab Reagents Gold
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
| Company Name: |
Leancare Ltd.
|
| Tel: |
+33 962096793 |
| Website: |
www.leancare.co.uk |
|